Rani Therapeutics director granted 123,600 options

Rani Therapeutics Holdings director Abraham Bassan received a grant of 123,600 stock options for Class A Common Stock.

Rhea-AI Filing Summary

Rani Therapeutics Holdings director Abraham Bassan received a grant of 123,600 stock options for Class A Common Stock. The options were awarded at an exercise price of $0.9515 per share and represent his entire reported derivative holdings after this transaction.

The option grant vests in full on the first anniversary of the grant date, subject to his continued service. Vesting may occur earlier if the company holds its next annual stockholder meeting or if a Change in Control occurs, provided he maintains Continuous Service through that date.

Insider Trade Summary

Grant/Award: 123,600 shares

Grant/Award 1 txn

Insider Bassan Abraham

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	123,600	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 123,600 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

Key Figures

Options granted: 123,600 options Exercise price: $0.9515 per share Underlying shares: 123,600 shares +2 more

5 metrics

Options granted 123,600 options Director stock option grant on 2026-05-28

Exercise price $0.9515 per share Strike price for granted options

Underlying shares 123,600 shares Class A Common Stock underlying the options

Post-transaction derivative holdings 123,600 options Total derivative securities held after grant

Expiration date 2036-05-27 Option expiration for the director grant

Key Terms

Director Stock Option (Right to Buy), Class A Common Stock, 2021 Equity Incentive Plan, Continuous Service, +1 more

5 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

Class A Common Stock financial

"underlying_security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

2021 Equity Incentive Plan financial

"defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")"

Continuous Service financial

"subject to the Reporting Person's Continuous Service through such vesting date"

Change in Control financial

"vest in full upon the occurrence of either ... a Change in Control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rani Therapeutics (RANI) report for Abraham Bassan?

Rani Therapeutics reported that director Abraham Bassan received a grant of 123,600 stock options. These options relate to Class A Common Stock and were awarded as a compensation grant rather than an open-market purchase or sale.

What is the exercise price of Abraham Bassan’s new Rani Therapeutics options?

The granted options have an exercise price of $0.9515 per share. This means Bassan can buy Class A Common Stock at that price once the options vest and are exercisable under the grant’s terms.

When do Abraham Bassan’s RANI stock options vest?

The options vest in full on the first anniversary of the grant date, subject to his Continuous Service. Vesting may occur earlier upon the company’s next annual stockholder meeting or a Change in Control, if he remains in Continuous Service through that date.

How many Rani Therapeutics shares underlie Abraham Bassan’s option grant?

The option grant covers 123,600 underlying shares of Rani Therapeutics Class A Common Stock. This full amount is reported as his total derivative holdings following the transaction in the Form 4 filing.

Is Abraham Bassan’s Form 4 transaction in RANI stock a market buy or sell?

The filing shows a grant of options classified as an acquisition, not a market buy or sell. The transaction code is A, indicating a grant or award of derivative securities as part of compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bassan Abraham

(Last) (First) (Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$0.9515	05/28/2026		A		123,600		(1)	05/27/2036	Class A Common Stock	123,600	$0	123,600	D

Explanation of Responses:

1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

	/s/ Svai Sanford, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)